Jan van Bodegom

Company: Coretag

Job title: Chief Executive Officer

Seminars:

Latest in Targeted Alpha Therapy: ²¹²Pb available for precision cancer therapy 12:45 pm

Single alpha-emitting isotopes: how to avoid delayed damage? Ideal half-life: can you combine effectiveness with minimal side effects? Reliable supply: how to secure a strong and reliable supply chainRead more

day: Day Two

Necrosis Targeting Radiopharmaceuticals 4:30 pm

Necrosis Targeting Diagnostics to help clinical decision making Necrosis Targeting Alpha and Beta therapy Necrosis Targeting Radiotherapy the path from concept to clinicRead more

day: Day One